Ramipril in Rheumatoid Arthritis
The present study is designed to evaluate the hypothesis that the Angiotensin‐Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis...
Brief Summary
Official Title: “Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis”
The present study is designed to evaluate the hypothesis that the Angiotensin‐Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Detailed Clinical Trial Description
The effect of an 8-week treatment with either ramipril or placebo is studied using a randomized, double-blind, and crossover protocol. After given written informed consent, baseline characteristics including physical examination, ECG, blood sample and a noninvasive assessment of endothelial function are obtained. The patients are randomly assigned to receive either ramipril 10mg (up-titration-scheme: starting with 2.5mg in Week1, then 5mg in Week2 followed by 2-5mg for the final 6 weeks) followed by placebo or vice versa.The individual disease-modifying antirheumatic drug therapy is continued throughout the study.
The examinations are repeated after 8 weeks treatment of the first and 8 weeks after the second study drug. At week 1 and 2 in each treatment period a safety visit is scheduled.
Intervention(s) in this Clinical Trial
- Drug: Ramipril
Outcome Measures for this Clinical Trial
Primary Measures
- Endothelial dysfunction evaluated on weeks 8 and 16.
Secondary Measures
- Alteration of inflammatory parameters: C-reactive Protein, TNFa, Interleukin 6 on weeks 8 and 16.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- patients with rheumatoid arthritis (4 out of 7 ARA criteria must be fulfilled to establish diagnosis) on stable background therapy for the last three months
- endothelial dysfunction (FMD < 4%, FMD:Flow-Mediated-Dilatation)
- non-smokers
Exclusion Criteria:
- previous myocardial infarction, coronary intervention or coronary surgery
- previous treatment with statins in the last 6 months
- previous treatment with ACE-inhibitors in the last 6 months
- uncontrolled hypertension SAP/DAP > 160/90 mmHg (SAP:Systolic Arterial Pressure, DAP:Diastolic Arterial Pressure)
- dyslipidemia (LDL-cholesterol > 4.9 mmol)
- normal CRP < 3 mg/l
- overweight BMI > 35kg/m2
- anaemia (hemoglobin < 10g/dl)
- kidney disease (creatinine > 150 umol/l)
- insulin-dependent diabetes mellitus
- congestive heart failure (> NYHA I)
- AV-Block>I
- pregnancy
- angio-edema
- malignancy or chronic infection
- drug abuse
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 60 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: University of Zurich Other
Overall Clinical Trial Officials and Contacts
Ali Shokry Study Director Sanofi-Aventis
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00273533
Study ID Number: HOE498/6007
ClinicalTrials.gov Identifier: NCT00273533
Health Authority: Switzerland: Swissmedic
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00273533
